Quick Answer
Vistagen Therapeutics, Inc. reported Cash and Equivalents of $67.13 million for fiscal year 2025.
Vistagen Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $67.13M | -43.7% |
| 2024 | $119.17M | +616.2% |
| 2023 | $16.64M | -75.6% |
| 2022 | $68.14M | -33.9% |
| 2021 | $103.11M | +7508.9% |
| 2020 | $1.36M | -89.7% |
| 2019 | $13.10M | +26.2% |
| 2018 | $10.38M | +255.3% |
| 2017 | $2.92M | +581.8% |
| 2016 | $428.5K | +512.1% |
| 2015 | $70.0K | -89.0% |
| 2013 | $638.1K | +687.8% |
| 2012 | $81.0K | -41.9% |
| 2011 | $139.3K | -30.7% |
| 2010 | $201.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $47.37M | -36.6% | -24.6% |
| September 30, 2025 | $62.79M | -25.5% | +28.2% |
| June 30, 2025 | $48.98M | -52.4% | -27.0% |
| March 31, 2025 | $67.13M | -43.7% | -10.2% |
| December 31, 2024 | $74.72M | -41.0% | -11.3% |
| September 30, 2024 | $84.25M | +124.0% | -18.1% |
| June 30, 2024 | $102.92M | +969.6% | -13.6% |
| March 31, 2024 | $119.17M | +616.2% | -5.8% |
- Vistagen Therapeutics, Inc. showed a decrease of -43.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, Vistagen Therapeutics, Inc.’s cash and equivalents has grown by 33298.5% (from $201.0 thousand to $67.13 million).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: